All updates
All updates
today 32中文产业新闻Chinese source评分2424 监管与产业动态评分4646 Duracyte: Turning the patient into the bioreactor
监管与产业动态评分3636 Viking commercial chief exits after nine months
监管与产业动态评分2121 Nurix drops one BTK degrader as momentum builds behind Roche-partnered option - Fierce Biotech
监管与产业动态评分1111 Galderma sculpts new narrative around menopausal skin changes to fill awareness gap - Fierce Pharma
监管与产业动态精选评分5353 Pfizer pens $500M Enodia pact to join Lilly in emerging protein degrader field - Fierce Biotech
监管与产业动态精选评分5656 Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race - Fierce Biotech
监管与产业动态评分2222 Biotech builder Paragon imports Apogee's top brass after AbbVie buyout - Fierce Biotech
监管与产业动态评分1414 UCB fashions ‘Wear It Out’ project with empowering t-shirts, community for inflammatory disease patients - Fierce Pharma
监管与产业动态评分1717 Insulet’s Omnipod Discover platform sees full market release in US - Fierce Biotech
监管与产业动态评分3434 BARDA awards Kaléo $96M contract to deploy auto-injector for chemical threat preparedness - Fierce Pharma
监管与产业动态评分1414 J&J’s new pharma chief expects Icotyde’s psoriasis launch momentum to repeat across indications - Fierce Pharma
监管与产业动态评分3333 Syndax shares fall 17% after calling it quits on Niktimvo fibrosis program - Fierce Pharma
中文产业新闻Chinese source评分3636 罗氏引进大睿生物ALK7靶向肥胖RNAi疗法，交易最高11.6亿美元
中文产业新闻Chinese source评分6868 大睿生物ALK7 siRNA授权罗氏，交易总额最高达11.6亿美元
中文产业新闻Chinese source评分6060 Zealand Pharma与Generate Biomedicines达成近12亿美元合作开发减重新药
BioPharma Dive精选评分5656 Another Paragon spinout goes public through reverse merger
STAT News精选评分7171 STAT+: BlackRock to buy majority stake in Humana’s CenterWell clinics for $2.8 billion
中文产业新闻精选Chinese source评分7676 诺华约77.75亿美元获艾博生物ABO2203全球权益，发力自免B细胞耗竭疗法
中文产业新闻Chinese source评分6767 大睿生物将 ALK7 RNAi 候选药全球独家许可给罗氏，交易总额最高11.6亿美元
中文产业新闻Chinese source评分6868 大睿生物与罗氏就肥胖候选药达成最高 11.6 亿美元出海合作
中文产业新闻Chinese source评分6969 大睿生物 ALK7 RNAi 候选药物超 11 亿美元授权罗氏
中文产业新闻Chinese source评分7070 大睿生物ALK7 siRNA出海 授予罗氏全球开发许可 最高12亿美元
中文产业新闻Chinese source评分6868 罗氏获大睿生物ALK7靶向RNAi候选物全球独家许可，总额近12亿美元
中文产业新闻Chinese source评分7272 恒瑞HRS-1596以26亿美元海外授权诺和诺德，改写GLP-1赛道竞争逻辑
中文产业新闻精选Chinese source评分7171 罗氏1亿美元首付获大睿生物ALK7肥胖症项目权益，总额最高11.6亿美元
中文产业新闻Chinese source评分4444 强生2026Q3：传奇CAR-T增长47%，IL-23单抗增长70%，双抗增长61%
中文产业新闻Chinese source评分6363 大睿生物与罗氏达成 ALK7 RNAi 全球独家许可合作，最高 11.6 亿美元
中文产业新闻Chinese source评分5858 辉瑞与Enodia达成超5亿美元合作 开发Sec61靶向小分子降解剂
中文产业新闻Chinese source评分4040 强生上调2026年业绩指引，Q3 CD38销售额42亿美元、CAR-T 7.1亿、A+L 3.2亿
中文产业新闻Chinese source评分3636 博士伦任命魏培康为临时CEO，继续兼任博士康CEO
BioPharma Dive评分6464 Roche extends China deal streak with $1B pact for RNAi obesity drug
BioSpace精选评分5252 J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent
STAT News评分3939 STAT+: FTC demands Martin Shkreli divest his pharma stocks
中文产业新闻Chinese source评分7070 大睿生物 ALK7 RNAi 减重候选药独家授权罗氏，总额超 77 亿元
中文产业新闻Chinese source评分2828 减重持续加码、增肌仍待突破：罗氏终止 Emugrobart 肥胖治疗开发
BioSpace评分6565 Roche expands obesity R&D footprint with Rona deal worth $1B+
BioSpace精选评分5656 Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins
中文产业新闻Chinese source评分6161 小核酸公司 ADARx IPO 募资约 40 亿元，艾伯维参与同步私募配售
中文产业新闻Chinese source评分6868 罗氏以11.6亿美元引进大睿生物ALK7 siRNA全球独家权益